David Y Oh
Overview
Explore the profile of David Y Oh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mennillo E, Lotstein M, Lee G, Johri V, Ekstrand C, Tsui J, et al.
bioRxiv
. 2024 Nov;
PMID: 39605355
Background & Aims: Imaging-based, single-cell spatial transcriptomics (iSCST) using formalin-fixed, paraffin-embedded (FFPE) tissue could transform translational research by retaining all tissue cell subsets and spatial locations while enabling the analysis...
2.
Mei R, Pepe E, Oh D, Tsai K, Chugh R, Kattah M
Inflamm Bowel Dis
. 2024 Nov;
PMID: 39495057
No abstract available.
3.
Montauti E, Oh D, Fong L
Trends Cancer
. 2024 Sep;
10(10):969-985.
PMID: 39242276
Advances in cancer immunotherapy have transformed cancer care and realized unprecedented responses in many patients. The growing arsenal of novel therapeutics - including immune checkpoint inhibition (ICI), adoptive T cell...
4.
Tsimberidou A, Alayli F, Okrah K, Drakaki A, Khalil D, Kummar S, et al.
J Exp Med
. 2024 Aug;
221(10).
PMID: 39190534
Identifying pan-tumor biomarkers that predict responses to immune checkpoint inhibitors (ICI) is critically needed. In the AMADEUS clinical trial (NCT03651271), patients with various advanced solid tumors were assessed for changes...
5.
He J, Kim Y, Mennillo E, Rusu I, Bain J, Rao A, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38642938
Background: Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear. Methods: Using colon biopsies...
6.
Mennillo E, Kim Y, Lee G, Rusu I, Patel R, Dorman L, et al.
Nat Commun
. 2024 Feb;
15(1):1493.
PMID: 38374043
Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to...
7.
Hassan R, Butler M, OCearbhaill R, Oh D, Johnson M, Zikaras K, et al.
Nat Med
. 2023 Jul;
29(8):2099-2109.
PMID: 37501016
The T cell receptor fusion construct (TRuC) gavocabtagene autoleucel (gavo-cel) consists of single-domain anti-mesothelin antibody that integrates into the endogenous T cell receptor (TCR) and engages the signaling capacity of...
8.
Mennillo E, Kim Y, Lee G, Rusu I, Patel R, Dorman L, et al.
bioRxiv
. 2023 Jan;
PMID: 36711576
Ulcerative colitis (UC) is driven by immune and stromal subsets, culminating in epithelial injury. Vedolizumab (VDZ) is an anti-integrin antibody that is effective for treating UC. VDZ is known to...
9.
Foy S, Jacoby K, Bota D, Hunter T, Pan Z, Stawiski E, et al.
Nature
. 2022 Nov;
615(7953):687-696.
PMID: 36356599
T cell receptors (TCRs) enable T cells to specifically recognize mutations in cancer cells. Here we developed a clinical-grade approach based on CRISPR-Cas9 non-viral precision genome-editing to simultaneously knockout the...
10.
Kwon H, Schafer J, Song N, Kaneko S, Li A, Xiao T, et al.
Sci Immunol
. 2022 Apr;
7(73):eabq2630.
PMID: 35420889
Sex bias exists in the development and progression of nonreproductive organ cancers, but the underlying mechanisms are enigmatic. Studies so far have focused largely on sexual dimorphisms in cancer biology...